Post by Helix Biogen Institute

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗮𝗻 𝗘𝗯𝗼𝗹𝗮 𝗕𝘂𝗻𝗱𝗶𝗯𝘂𝗴𝘆𝗼 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗖𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲 Helix Biogen Institute is proud to join a strategic consortium advancing the development of an #Ebola #Bundibugyo vaccine candidate in response to the recent CEPI (Coalition for Epidemic Preparedness Innovations) Call for Proposals on rapid vaccine development against priority pathogens. Working alongside leading scientists and institutions in #Kenya and #South #Africa, with the support of Africa CDC, this initiative represents a significant step toward strengthening Africa's capacity to develop locally led solutions for emerging infectious disease threats. Building on our track record, including the recognition of our COVID-19 vaccine candidate on the World Health Organization Draft Landscape of COVID-19 Candidate Vaccines, we remain committed to advancing scientific innovation, strengthening regional partnerships, and contributing to global health security. Together, we are helping shape a future where Africa develops and delivers solutions for Africa and the world. Dr. Oladipo Elijah Kolawole (Ph.D) Oluwaseyi Akinpelu James Ogunniran Nigerian Institute of Medical Research (NIMR) Nigeria mRNA vaccines Consortium (NmRNA-VC) Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) German-West African Centre for Global Health and Pandemic Prevention Pandemic Sciences Institute Africa Pandemic Sciences Collaborative #CEPI #Ebola #Bundibugyo #VaccineCandidate #VaccineDevelopment #AfricaCDC #GlobalHealthSecurity #AfricanScience #HelixBiogen